Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

EU Funding for Clinical Trials of a Placental Malaria Vaccine

Published: Tuesday, March 05, 2013
Last Updated: Monday, March 04, 2013
Bookmark and Share
PlacMalVac project has received an FP7 EU grant.

PlacMalVac - a project coordinated by University of Copenhagen has received an FP7 EU grant, which will enable the first clinical trial of a VAR2CSA based vaccine to target malaria parasites infecting pregnant women.

The international consortium includes the Centre for Medical Parasitology (CMP) from University of Copenhagen (Denmark), ExpreS2ion Biotechnologies (Denmark), Institut de Recherche pour le Développement (France), European Vaccine Initiative (EVI, Germany), Université d'Abomey-Calavi (Benin), & University of Tübingen (Germany).

The clinical development program was initiated in 2012 with support from the Danish National Advanced Technology Foundation.

Professor Ali Salanti from the University of Copenhagen: “The funding from DNATF allowed us to commence a very ambitious and high risk vaccine development project, and in this project we managed to define and show proof of concept for the malaria vaccine and we are currently addressing manufacturability of the vaccine. The funding from EU FP7 will enable us to continue the development including upstream and downstream process development, GMP production, Phase Ia and Ib human clinical trials, as well as preparations for Phase II clinical trials."

Professor Thor G. Theander from the University of Copenhagen: “This will be the first clinical trial using the parasite antigens that cause severe disease syndromes. The vaccine attempts not to eliminate the infection but to eliminate the disease. At Centre for Medical Parasitology we are all thrilled to have this opportunity and it marks an intermediate highpoint of many years of committed research. If the vaccine is safe it will, however, require many years of continued international support before it can help pregnant women and their unborn children.”

Dr. Charlotte Dyring, CEO of ExpreS2ion Biotechnologies: “We are proud to be part of this significant effort in the fight against malaria. Our partnership with CMP has allowed us to leverage our Drosophila S2 cells-based protein expression platform capabilities to contribute to developing a potential vaccine for the millions of people impacted by placental malaria. Our platform is very well suited for production of complex and challenging antigens and has good scalability, which is one of the reasons why it is the choice of expression platform for this and other malaria projects."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genetic Aberration Paves the Way for New Treatment of Cancer Disease
Research was recently published in Scandinavian Journal of Gastroenterology.
Friday, November 08, 2013
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos